Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Retained Earnings (2021 - 2026)

TriSalus Life Sciences has reported Retained Earnings over the past 6 years, most recently at -$329.0 million for Q1 2026.

  • For Q1 2026, Retained Earnings fell 13.49% year-over-year to -$329.0 million; the TTM value through Mar 2026 reached -$329.0 million, down 13.49%, while the annual FY2025 figure was -$330.6 million, 18.26% down from the prior year.
  • Retained Earnings for Q1 2026 was -$329.0 million at TriSalus Life Sciences, roughly flat from -$330.6 million in the prior quarter.
  • Over five years, Retained Earnings peaked at -$11.5 million in Q2 2022 and troughed at -$330.6 million in Q4 2025.
  • A 5-year average of -$197.6 million and a median of -$261.6 million in 2024 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: grew 0.19% in 2023 and later crashed 1788.1% in 2024.
  • Year by year, Retained Earnings stood at -$186.4 million in 2022, then plummeted by 33.88% to -$249.5 million in 2023, then fell by 12.04% to -$279.5 million in 2024, then fell by 18.26% to -$330.6 million in 2025, then rose by 0.47% to -$329.0 million in 2026.
  • Business Quant data shows Retained Earnings for TLSI at -$329.0 million in Q1 2026, -$330.6 million in Q4 2025, and -$321.0 million in Q3 2025.